Annual report pursuant to section 13 and 15(d)

Note Payable - Additional Information (Detail)

Note Payable - Additional Information (Detail) (USD $)
12 Months Ended
Sep. 30, 2013
Apr. 19, 2013
Note Payable [Line Items]    
Class of Warrant or Right, Exercise Price of Warrants or Rights   0.75
Notes Payable, Total $ 944,707  
Adjustments to Additional Paid in Capital, Warrant Issued 55,293  
Note Payable [Line Items]    
Fair Value Assumptions, Risk Free Interest Rate 2.64%  
Fair Value Assumptions, Expected Dividend Rate 0.00%  
Fair Value Assumptions, Expected Term 10 years  
Fair Value Assumptions, Expected Volatility Rate 114.00%  
Massachusetts Life Sciences Center
Note Payable [Line Items]    
Subordinated Debt $ 1,000,000  
Debt Instrument, Payment Terms The loan bears interest at a rate of 10% per annum, and will become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction or one or more financing transactions in which we receive net proceeds of $5,000,000 or more in a 12-month period.  
Warrants Issued To Purchase Of Common Stock 145,985  
Class of Warrant or Right, Exercise Price of Warrants or Rights 0.27  
Class Of Warrant Or Right Expiration Date Sep. 30, 2023